GERON CORP Marketable Securities, Unrealized Gain (Loss)
GERON CORP (GERN) reported Marketable Securities, Unrealized Gain (Loss) of -$6.00 thousand for the 6-month period ending 2012-06-30, per its 10-Q filed 2012-08-03.
Discontinued › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2012-08-03
- 2012-06-30: Marketable Securities, Unrealized Gain (Loss) 6 month -$6.00K.
- 2011-06-30: Marketable Securities, Unrealized Gain (Loss) 6 month $42.00K.
| Period end | Marketable Securities, Unrealized Gain (Loss) 6 month |
|---|---|
| 2012-06-30 | -$6.00K 10-Q · filed 2012-08-03 |
| 2011-06-30 | $42.00K 10-Q · filed 2012-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |